Two patients developed intraocular inflammation with extramacular vascular occlusion after one and two injections, respectively, needing systemic corticosteroid treatment and the discontinuation of brolucizumab therapy, followed by a switch back to the previous anti-VEGF agents. This evidence concerns the gene VEGFA and inflammatory response.